Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggestNovember 25, 2020Genitourinary CancerMelanomaCOVID-19 UpdatesOncologyLung Cancer
Neoadjuvant immunotherapy combo produces high response rate in melanomaNovember 25, 2020MelanomaOncologyHematologic Malignancies
Real-world results with checkpoint inhibitors found inferior to trial resultsOctober 30, 2020Lung CancerMelanomaGenitourinary Cancer
Lower BP and better tumor control with drug combo?October 26, 2020Lung CancerBreast CancerGenitourinary CancerMelanoma
Are oncologists ready to confront a second wave of COVID-19?October 21, 2020Breast CancerCOVID-19 UpdatesGenitourinary CancerLung CancerMelanomaHematologic Malignancies
The scope of under- and overtreatment in older adults with cancerOctober 1, 2020Breast CancerGenitourinary CancerLung CancerMelanomaRare DiseasesOncology
Survey quantifies COVID-19’s impact on oncologySeptember 20, 2020COVID-19 UpdatesBreast CancerLung CancerGenitourinary CancerMelanomaAMLMultiple Myeloma
COVID-19 prompts ‘democratization’ of cancer trialsSeptember 16, 2020COVID-19 UpdatesGenitourinary CancerLung CancerMelanomaRare DiseasesOncology
Immunotherapy should not be withheld because of sex, age, or PSAugust 27, 2020Lung CancerMelanomaBreast CancerGenitourinary CancerOncology
Aspirin may accelerate cancer progression in older adultsAugust 27, 2020Breast CancerGenitourinary CancerLung CancerMelanomaOncology
COVID-19 impact: Less chemo, immune checkpoint inhibitors, and steroidsAugust 14, 2020Genitourinary CancerLung CancerMelanomaCOVID-19 Updates
Artificial intelligence matches cancer genotypes to patient phenotypesAugust 10, 2020Breast CancerLung CancerMelanomaGenitourinary CancerOncology
Study: Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19August 7, 2020Lung CancerCOVID-19 UpdatesMelanomaGenitourinary CancerOncology
